Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALTSNASDAQ:CELUNASDAQ:EDITNASDAQ:ELDN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTSALT5 Sigma$9.47+3.4%$7.25$1.29▼$10.95$159.88M2.31230,192 shs384,076 shsCELUCelularity$1.76-1.7%$1.86$1.00▼$5.22$42.87M0.77336,217 shs66,343 shsEDITEditas Medicine$2.22-5.5%$1.67$0.91▼$6.05$196.73M2.12.59 million shs3.06 million shsELDNEledon Pharmaceuticals$2.72-2.2%$3.04$2.30▼$5.54$166.47M-0.17276,703 shs244,846 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTSALT5 Sigma+3.38%-7.70%+42.62%+100.21%+946,999,900.00%CELUCelularity-1.68%+0.57%-16.19%-3.30%-40.94%EDITEditas Medicine-5.53%+12.69%+48.00%+69.47%-55.95%ELDNEledon Pharmaceuticals-2.16%-5.23%-13.65%-22.51%+4.21%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTSALT5 Sigma0.2043 of 5 stars0.03.00.00.01.80.00.0CELUCelularity0.0817 of 5 stars0.02.00.00.00.01.70.0EDITEditas Medicine3.806 of 5 stars3.22.00.04.21.42.50.6ELDNEledon Pharmaceuticals2.7508 of 5 stars3.54.00.00.02.91.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTSALT5 Sigma 0.00N/AN/AN/ACELUCelularity 0.00N/AN/AN/AEDITEditas Medicine 2.31Hold$4.70111.71% UpsideELDNEledon Pharmaceuticals 3.00Buy$9.00230.88% UpsideCurrent Analyst Ratings BreakdownLatest CELU, ELDN, ALTS, and EDIT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025ELDNEledon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$9.005/13/2025EDITEditas MedicineRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$8.00 ➝ $4.004/29/2025EDITEditas MedicineCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/28/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.004/28/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$3.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTSALT5 Sigma$12.53M13.19N/AN/A$0.49 per share19.33CELUCelularity$54.22M0.78N/AN/A$0.37 per share4.76EDITEditas Medicine$32.31M5.75N/AN/A$1.63 per share1.36ELDNEledon PharmaceuticalsN/AN/AN/AN/A$1.98 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTSALT5 Sigma-$6.24MN/A0.00∞N/A-38.58%-113.79%-8.96%N/ACELUCelularity-$57.89M-$2.65N/A∞N/A-106.77%-271.88%-42.82%7/28/2025 (Estimated)EDITEditas Medicine-$237.09M-$3.04N/AN/AN/A-701.06%-139.24%-63.87%8/6/2025 (Estimated)ELDNEledon Pharmaceuticals-$36.18M-$2.10N/AN/AN/AN/A-79.54%-41.62%8/18/2025 (Estimated)Latest CELU, ELDN, ALTS, and EDIT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ELDNEledon Pharmaceuticals-$0.28-$0.08+$0.20-$0.08N/AN/A5/12/2025Q1 2025EDITEditas Medicine-$0.51-$0.43+$0.08-$0.92$0.79 million$4.66 million5/8/2025Q4 2024CELUCelularity-$1.50-$0.59+$0.91-$0.59$5.20 million$18.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTSALT5 SigmaN/AN/AN/AN/AN/ACELUCelularityN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTSALT5 Sigma1.260.830.83CELUCelularity4.070.380.28EDITEditas MedicineN/A3.083.08ELDNEledon PharmaceuticalsN/A13.9013.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTSALT5 Sigma6.27%CELUCelularity19.02%EDITEditas Medicine71.90%ELDNEledon Pharmaceuticals56.77%Insider OwnershipCompanyInsider OwnershipALTSALT5 Sigma4.90%CELUCelularity22.10%EDITEditas Medicine2.10%ELDNEledon Pharmaceuticals12.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTSALT5 Sigma17017.45 million16.60 millionN/ACELUCelularity22023.95 million18.66 millionOptionableEDITEditas Medicine23083.71 million81.96 millionOptionableELDNEledon Pharmaceuticals1059.88 million52.52 millionOptionableCELU, ELDN, ALTS, and EDIT HeadlinesRecent News About These CompaniesAnalysts Issue Forecasts for ELDN Q1 EarningsJune 19 at 7:24 AM | marketbeat.comEledon Pharmaceuticals (NASDAQ:ELDN) Earns Buy Rating from Analysts at HC WainwrightJune 19 at 2:51 AM | americanbankingnews.comEledon Pharmaceuticals' (ELDN) "Buy" Rating Reaffirmed at HC WainwrightJune 18 at 8:05 AM | marketbeat.comBank of America Corp DE Increases Stock Holdings in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)June 13, 2025 | marketbeat.comMillennium Management LLC Invests $490,000 in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)June 9, 2025 | marketbeat.comEledon Pharmaceuticals (NASDAQ:ELDN) Downgraded by Wall Street Zen to "Sell"June 7, 2025 | marketbeat.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Down 12.3% in MayJune 4, 2025 | marketbeat.comJane Street Group LLC Makes New $504,000 Investment in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)May 31, 2025 | marketbeat.comWoodline Partners LP Boosts Stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)May 26, 2025 | marketbeat.comEledon Pharmaceuticals (NASDAQ:ELDN) Rating Increased to Hold at Wall Street ZenMay 24, 2025 | marketbeat.comWhat Makes Eledon Pharmaceuticals (ELDN) a New Buy StockMay 23, 2025 | zacks.com1,100,473 Shares in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Acquired by AWM Investment Company Inc.May 23, 2025 | marketbeat.comEquities Analysts Offer Predictions for ELDN Q2 EarningsMay 23, 2025 | marketbeat.comFrazier Life Sciences Management L.P. Invests $4.85 Million in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)May 23, 2025 | marketbeat.comZimmer Partners LP Has $3.09 Million Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)May 23, 2025 | marketbeat.comPoint72 Asset Management L.P. Purchases New Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)May 22, 2025 | marketbeat.comVelan Capital Investment Management LP Purchases New Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)May 21, 2025 | marketbeat.comFY2025 EPS Estimates for ELDN Boosted by Cantor FitzgeraldMay 21, 2025 | marketbeat.comCantor Fitzgerald maintains Overweight on Eledon Pharmaceuticals stockMay 17, 2025 | uk.investing.comEledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial ResultsMay 14, 2025 | globenewswire.comEledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance SheetMay 3, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCELU, ELDN, ALTS, and EDIT Company DescriptionsALT5 Sigma NASDAQ:ALTS$9.47 +0.31 (+3.38%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$9.34 -0.14 (-1.43%) As of 06/20/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.Celularity NASDAQ:CELU$1.76 -0.03 (-1.68%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.76 0.00 (0.00%) As of 06/20/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.Editas Medicine NASDAQ:EDIT$2.22 -0.13 (-5.53%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.19 -0.03 (-1.13%) As of 06/20/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Eledon Pharmaceuticals NASDAQ:ELDN$2.72 -0.06 (-2.16%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.72 -0.01 (-0.18%) As of 06/20/2025 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
